Enteral fluconazole population pharmacokinetics in patients in the surgical intensive care unit

Pharmacotherapy

Volumn 23, Issue 5, 2003, Pages 592-602

  Rajagopalan, Prabhu ^a   Pelz, Robert K ^b   Lipsett, Pamela A ^b   Swoboda, Sandra M ^b   Rinaldi, Michael G ^c   Hendrix, Craig W ^b,d  

^a BAYER CORPORATION   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Mays Cancer Center at UT Health San Antonio   (United States)

^d Harvey 502 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; FLUCONAZOLE;

ADULT; AGE DISTRIBUTION; AGED; ANALYTIC METHOD; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CLINICAL TRIAL; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; FEMALE; GAS LIQUID CHROMATOGRAPHY; HUMAN; INFORMED CONSENT; INTENSIVE CARE UNIT; INTUBATION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MYCOSIS; PATIENT; POPULATION MODEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SUSPENSION; UNIVERSITY HOSPITAL;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; BIOLOGICAL AVAILABILITY; BODY WEIGHT; CREATININE; DRUG ADMINISTRATION ROUTES; FEMALE; FLUCONAZOLE; HALF-LIFE; HUMANS; INTENSIVE CARE; INTENSIVE CARE UNITS; KIDNEY DISEASES; LINEAR MODELS; MALE; MIDDLE AGED; MYCOSES; PROSPECTIVE STUDIES;

EID: 0038031860     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.5.592.32202     Document Type: Article

References (30)

1. Goa KL, Barradell LB. Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 1995;50:658-90.
2. Nicolau DP, Crowe H, Nightingale CH, Quintiliani R. Bioavailability of fluconazole administered via a feeding tube in intensive care unit patients. J Antimicrob Chemother 1995;36:395-401.
3. Buijk SL, Gyssens IC, Mouton JW, et al. Pharmacokinetics of sequential intravenous and enteral fluconazole in critically ill surgical patients with invasive mycoses and compromised gastrointestinal function. Intensive Care Med 2001;27:115-21.
4. Rosemurgy AS, Markowsky S, Goode SE, Plastino K, Kearney RE. Bioavailability of fluconazole in surgical intensive care unit patients: a study comparing routes of administration. J Trauma 1995;39:445-7.
5. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845-51.
6. Winston DJ, Pakrasi A, Busuttil RW. Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999;131:729-37.
7. Winston DJ, Chandrasekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993;118:495-503.
8. Eggimann P, Francioli P, Bille J, et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 1999;27:1066-72.
9. Pelz RK, Hendrix CW, Swoboda SM, et al. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 2001;233:542-8.
10. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
11. Harris SC, Wallace JE, Foulds G, Rinaldi MG. Assay of fluconazole by megabore capillary gas-liquid chromatography with nitrogen-selective detection. Antimicrob Agents Chemother. 1989;33:714-16.
12. McLachlan AJ, Tett SE. Pharmacokinetics of fluconazole in people with HIV infection: a population analysis. Br J Clin Pharmacol 1996;41:291-8.
13. Csajka C, Decosterd LA, Buclin T, et al. Population pharmacokinetics of fluconazole given for secondary prevention of oropharyngeal candidiasis in HIV-positive patients. Eur J Clin Pharmacol 2001;57:723-7.
14. Toon S, Ross CE, Gokal R, Rowland M. An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole. Br J Clin Pharmacol 1990;29:221-6.
15. Beal SL, Sheiner LB. NONMEM users guide, NONMEM project group. San Francisco: University of California at San Francisco, 1992.
16. Nicolau DP, Crowe HM, Nightingale CH, Quintiliani R. Rifampin-fluconazole interaction in critically ill patients. Ann Pharmacother 1995;29:994-6.
17. Apseloff G, Hilligoss DM, Gardner MJ, et al. Induction of fluconazole metabolism by rifampin: in vivo study in humans. J Clin Pharmacol 1991;31:358-61.
18. Blum RA, Wilton JH, Hilligoss DM, et al. Effect of fluconazole on the disposition of phenytoin. Clin Pharmacol Ther 1991;49:420-5.
19. Jezequel SG. Fluconazole: interspecies scaling and allometric relationships of pharmacokinetic properties. J Pharm Pharmacol 1994;46:196-9.
20. Tett S, Moore S, Ray J. Pharmacokinetics and bioavailability of fluconazole in two groups of males with human immunodeficiency virus (HIV) infection compared with those in a group of males without HIV infection. Antimicrob Agents Chemother 1995;39:1835-41.
21. DeMuria D, Forrest A, Rich J, et al. Pharmacokinetics and bioavailability of fluconazole in patients with AIDS. Antimicrob Agents Chemother 1993;37:2187-92.
22. McKindley DS, Boucher BA, Hess MM, Croce MA, Fabian TC. Pharmacokinetics of aztreonam and imipenem in critically ill patients with pneumonia. Pharmacotherapy 1996;16:924-31.
23. van Dalen R, Vree TB. Pharmacokinetics of antibiotics in critically ill patients. Intensive Care Med 1990;16:S235-8.
24. Niemiec PW, Allo MD, Miller CF. Effect of altered volume of distribution on aminoglycoside levels in patients in surgical intensive care. Arch Surg 1987;122:207-12.
25. Hess MM, Boucher BA, Laizure SC, et al. Trimethoprim-sulfamethoxazole pharmacokinetics in trauma patients. Pharmacotherapy 1993;13:602-6.
26. Beckhouse MJ, Whyte IM, Byth PL, Napier JC, Smith AJ. Altered aminoglycoside pharmacokinetics in the critically ill. Anaesth Intensive Care 1988;16:418-22.
27. Swift CG, Triggs EJ. Clinical pharmacokinetics in the elderly. In: Swift CG, ed. Clinical pharmacology in the elderly. New York: Marcel Dekker, Inc., 1987:31-82.
28. Wade JR, Kelman AW, Howie CA, Whiting B. Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis. J Pharmacokinet Biopharm 1993;21:209-22.
29. Pelz RK, Lipsett PA, Swoboda SM, et al. Enteral fluconazole is well absorbed in critically ill surgical patients. Surgery 2002;131:534-40.
30. Zimmermann T, Yeates RA, Laufen H, Pfaff G, Wildfeuer A. Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol 1994;46:147-50.